KJ-C2320

N/A

Report date: 2026/01/21 16:21:04

Base Information

Drug NameKJ-C2320
Drug Alias NameKJ-C2320
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionLymphocyte differentiation antigen CD38 modulatorsT lymphocyte replacements
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCARsgen Therapeutics Holdings Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCARsgen Therapeutics Holdings Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A